Table 1 Relationship between SLC25A10 and clinicopathological features in patients with cervical cancer (case (%)).
From: SLC25A10 promotes cisplatin resistance by inhibiting ferroptosis in cervical cancer
Parameters | n | SLC25A10 | χ2, p | ||
|---|---|---|---|---|---|
|  |  |  | Negative (n = 20) | Positive (n = 47) | |
Age | ≤58 years old | 39 | 14 (35.9) | 25(64.1) | 1.629, 0.202 |
| Â | >58 years old | 28 | 6 (21.4) | 22 (78.6) | Â |
Histopathological type | Squamous | 48 | 14 (29.2) | 34 (70.8) | 0.038, 0.846 |
| Â | Nonsquamous | 19 | 6 (31.6) | 13 (68.4) | Â |
Differentiation | High | 3 | 3 (15.0) | 0 (0.0) | 16.803, <0.001*** |
| Â | Middle | 40 | 16 (80.0) | 24 (51.1) | Â |
| Â | Low | 24 | 1 (5.0) | 23 (48.9) | Â |
Lymph node metastasis | No | 48 | 19 (39.6) | 29 (60.4) | 6.105, 0.013* |
| Â | Yes | 19 | 1 (5.3) | 18 (94.7) | Â |
FIGO Stage | I | 32 | 18 (56.3) | 14 (43.8) | 20.297, <0.001*** |
| Â | II | 28 | 2 (7.1) | 26 (92.9) | Â |
| Â | III-IV | 7 | 0 (0.0) | 7 (100.0) | Â |
